Satellos Bioscience has announced a change to the primary endpoint in its Phase 2 BASECAMP clinical trial evaluating forazapadin, an investigational oral, small molecule designed to enhance skeletal muscle repair and regeneration in individuals living with Duchenne. Following feedback from the U.S. Food and Drug Administration (FDA), the company has indicated that it will replace dynamometry (a measure of muscle strength) with MRI-measured muscle fat fraction as the study’s primary efficacy endpoint.
BASECAMP is evaluating forazapadin in 53 ambulatory boys living with Duchenne, ages 7–9. The study’s initial 12-week period compares forazapadin with placebo, followed by 36 weeks in which all participants receive the investigational therapy. According to Satellos, the company believes MRI-measured fat fraction, alongside clinical measures, may help demonstrate the potential biological activity of forazapadin and support a possible accelerated approval pathway. Satellos expects to report topline results from the 12-week placebo-controlled period in Q1 2027.
PPMD has long recognized the importance of developing and validating reliable biomarkers and outcome measures to help researchers better understand Duchenne, improve clinical trial design, and evaluate potential therapies. As part of PPMD’s Biomarker Initiative, we have supported research on MRI-measured Fat Fraction over the years, most recently with our 2025 award to Dr. Sarah Kim.
We are pleased to learn this development from Satellos and look forward to future updates. We will continue to share information with the community as additional details become available.
Read Satellos’ press release here.
The post Satellos Announces Change to Primary Endpoint in BASECAMP Duchenne Trial appeared first on Parent Project Muscular Dystrophy.